Last reviewed · How we verify
NCT04380077
Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics
NA trial testing vitrectomy with sulfur hexafluoride gas in Proliferative Diabetic Retinopathy in 150 participants. Status unknown.
21 January 2025
Quick facts
| Lead sponsor | Rush Eye Associates |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 15 May 2020 |
| Primary completion | 21 January 2025 |
| Estimated completion | 21 January 2025 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- vitrectomy with sulfur hexafluoride gas
- vitrectomy with balanced salt solution
Conditions studied
- Proliferative Diabetic Retinopathy — all drugs for Proliferative Diabetic Retinopathy →
Sponsor
Rush Eye Associates
Who can join
Adults 18 to 85, any sex, with Proliferative Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hypothesis: Patients undergoing pars plana vitrectomy for the indication of diabetic vitreous hemorrhage will have a lower incidence of postoperative vitreous hemorrhaging during the 6-month trial period when vitreous substitution with 20-30% sulfur hexafluoride gas is utilized compared to vitreous substitution with balanced salt solution.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04380077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Proliferative Diabetic Retinopathy
Currently open trials in the same condition.
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Rush Eye Associates trials
Trials by the same sponsor.
- NCT04903301 — Patient Satisfaction With Contoura Vision Topography-Guided LASIK · NA · completed
- NCT04380064 — Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy · NA · unknown
- NCT03660345 — PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME · Phase 3 · completed
- NCT03660371 — ILM Peeling in PDR Patients Undergoing PPV for VH · NA · completed
- NCT03660384 — Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04380077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rush Eye Associates
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing